Literature DB >> 23369413

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis.

Julia A Critchley1, Fiona Young, Lois Orton, Paul Garner.   

Abstract

BACKGROUND: The effects of corticosteroids are systemic, but their benefits in tuberculosis are thought to be organ specific, with clinicians using them routinely to treat some forms of tuberculosis (such as meningitis), but not others. We aimed to assess the effects of steroids on mortality attributable to all forms of tuberculosis across organ systems.
METHODS: We did a systematic review and meta-analysis to estimate the efficacy of steroids for the prevention of mortality in all forms of tuberculosis, and to quantify heterogeneity in this outcome between affected organ systems. We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Central Register of Controlled Trials, Medline, Embase, and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) for studies published up to Sept 6, 2012, and checked reference lists of included studies and relevant reviews. We included all trials in people with tuberculosis in any organ system, with tuberculosis defined clinically or microbiologically. There were no restrictions by age, comorbidity, publication language, or type, dose, or duration of steroid treatment. We used the Mantel-Haenszel method to summarise mortality across trials.
FINDINGS: We identified 41 eligible trials, 18 of which assessed pulmonary tuberculosis. 20 of the 41 trials (including 13 of those for pulmonary tuberculosis) were done before the introduction of modern rifampicin-containing antituberculosis chemotherapy. Meta-analysis stratified by affected organ systems identified no heterogeneity; steroids reduced mortality by 17% (risk ratio [RR] 0·83, 95% CI 0·74-0·92; I(2) 0%), consistent across all organ groups. In a sensitivity analysis that only included trials that used rifampicin-containing regimens, the results were similar (RR 0·85, 95% CI 0·74-0·98; I(2) 21%). A sensitivity analysis in pulmonary tuberculosis that excluded trials with high potential risks of bias suggested a slight benefit, but the point estimate was closer to no effect and the difference was not significant (RR 0·93, 95% CI 0·60-1·44).
INTERPRETATION: Steroids could be effective in reducing mortality for all forms of tuberculosis, including pulmonary tuberculosis. However, further evidence is needed since few recent trials have assessed the effectiveness of corticosteroids in patients with pulmonary tuberculosis. FUNDING: UK Department for International Development.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23369413     DOI: 10.1016/S1473-3099(12)70321-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  56 in total

Review 1.  Hepatic and Intra-abdominal Tuberculosis: 2016 Update.

Authors:  Richard P T Evans; Moustafa Mabrouk Mourad; Lee Dvorkin; Simon R Bramhall
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

2.  Imatinib Triggers Phagolysosome Acidification and Antimicrobial Activity against Mycobacterium bovis Bacille Calmette-Guérin in Glucocorticoid-Treated Human Macrophages.

Authors:  Julia Steiger; Alexander Stephan; Megan S Inkeles; Susan Realegeno; Heiko Bruns; Philipp Kröll; Juliana de Castro Kroner; Andrea Sommer; Marina Batinica; Lena Pitzler; Rainer Kalscheuer; Pia Hartmann; Georg Plum; Steffen Stenger; Matteo Pellegrini; Bent Brachvogel; Robert L Modlin; Mario Fabri
Journal:  J Immunol       Date:  2016-05-27       Impact factor: 5.422

Review 3.  Host-Directed Therapies for Tuberculosis.

Authors:  David M Tobin
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-18       Impact factor: 6.915

Review 4.  Tracheobronchial tuberculosis: a clinical review.

Authors:  Wen Ting Siow; Pyng Lee
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

Review 5.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 6.  The pregnane X receptor in tuberculosis therapeutics.

Authors:  Amina I Shehu; Guangming Li; Wen Xie; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-12-05       Impact factor: 4.481

7.  Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.

Authors:  Bongani M Mayosi; Mpiko Ntsekhe; Jackie Bosch; Shaheen Pandie; Hyejung Jung; Freedom Gumedze; Janice Pogue; Lehana Thabane; Marek Smieja; Veronica Francis; Laura Joldersma; Kandithalal M Thomas; Baby Thomas; Abolade A Awotedu; Nombulelo P Magula; Datshana P Naidoo; Albertino Damasceno; Alfred Chitsa Banda; Basil Brown; Pravin Manga; Bruce Kirenga; Charles Mondo; Phindile Mntla; Jacob M Tsitsi; Ferande Peters; Mohammed R Essop; James B W Russell; James Hakim; Jonathan Matenga; Ayub F Barasa; Mahmoud U Sani; Taiwo Olunuga; Okechukwu Ogah; Victor Ansa; Akinyemi Aje; Solomon Danbauchi; Dike Ojji; Salim Yusuf
Journal:  N Engl J Med       Date:  2014-09-01       Impact factor: 91.245

Review 8.  A 43-year systematic review and meta-analysis: case-fatality and risk of death among adults with tuberculous meningitis in Africa.

Authors:  Yohannes W Woldeamanuel; Belaineh Girma
Journal:  J Neurol       Date:  2013-08-21       Impact factor: 4.849

Review 9.  Tuberculosis Meningitis.

Authors:  Kassem Bourgi; Christina Fiske; Timothy R Sterling
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

10.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.